Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 3/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.34 |
| ▸ | PHGDH | O43175 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5353571 | 1.00 | SYK (0.36) | SYKSERPINE1EGFRAURKBALDH1A1 | |
| SCHEMBL5361454 | 0.92 | SYK (0.38) | SYKSERPINE1EGFRAURKBALDH1A1 | |
| SCHEMBL5361450 | 0.92 | SYK (0.38) | SYKSERPINE1EGFRAURKBALDH1A1 | |
| SCHEMBL5356490 | 0.92 | SYK (0.37) | SYKSERPINE1ALDH1A1MAPTKDM4E | |
| SCHEMBL5356485 | 0.92 | SYK (0.37) | SYKSERPINE1ALDH1A1MAPTKDM4E | |
| SCHEMBL4042717 | 0.85 | SYK (0.36) | SYKSERPINE1ALDH1A1MAPTKDM4E | |
| SCHEMBL4042712 | 0.85 | SYK (0.36) | SYKSERPINE1ALDH1A1MAPTKDM4E | |
| SCHEMBL5357155 | 0.84 | SYK (0.40) | SYKSERPINE1ALDH1A1MAPTKDM4E | |
| SCHEMBL5357148 | 0.84 | SYK (0.40) | SYKSERPINE1ALDH1A1MAPTKDM4E | |
| SCHEMBL5351934 | 0.83 | SYK (0.39) | SYKSERPINE1ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253281-B2 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070106076-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles | BENTLEY JONATHAN M | 2007-05-10 | — | — | US | disclosed |
| US-20050239789-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a] indoles | BENTLEY JONATHAN M | 2005-10-27 | — | — | US | disclosed |
| EP-1325008-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2005-10-05 | — | — | EP | disclosed |
| US-6933387-B2 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles | HOFFMANN-LA ROCHE INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-20030216401-A1 | Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-20 | — | — | US | disclosed |
| EP-1325008-A1 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-09 | — | — | EP | disclosed |
| US-20020035110-A1 | Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles | VERNALIS RESEARCH LIMITED, A BRITISH COMPANY (GB) | 2002-03-21 | — | — | US | disclosed |
| WO-2002010169-A1 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239789-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a] indoles | GPR119, INSR, GIPR | SYK 3413/4885SERPINE1 3768/4885EGFR 3747/4885 |
| US-20030216401-A1 | Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles | GPR119, INSR, IRS1 | SYK 4160/4885SERPINE1 2358/4885EGFR 4550/4885 |
| US-20070106076-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles | GPR119, INSR, GIPR | SYK 3413/4885SERPINE1 3768/4885EGFR 3747/4885 |
| US-20020035110-A1 | Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles | GPR119, HTR1D, HTR1A | SYK 3324/4885SERPINE1 2396/4885EGFR 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.